5-bromo-2-[(2-chloro-4-iodophenyl)amino]-N-(cyclopropylmethoxy)-3,4-difluorobenzamide

• ChemBase ID: 154814
• Molecular Formular: C17H13BrClF2IN2O2
• Molecular Mass: 557.5555964
• Monoisotopic Mass: 555.88617179
• SMILES: c1cc(c(cc1I)Cl)Nc1c(cc(c(c1F)F)Br)C(=O)NOCC1CC1
• Canonical SMILES: Ic1ccc(c(c1)Cl)Nc1c(cc(c(c1F)F)Br)C(=O)NOCC1CC1
• InChI: InChI=1S/C17H13BrClF2IN2O2/c18-11-6-10(17(25)24-26-7-8-1-2-8)16(15(21)14(11)20)23-13-4-3-9(22)5-12(13)19/h3-6,8,23H,1-2,7H2,(H,24,25)
• InChIKey: VJNZMSLGVUSPCF-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: 5-bromo-2-[(2-chloro-4-iodophenyl)amino]-N-(cyclopropylmethoxy)-3,4-difluorobenzamide
• IUPAC Traditional name: 5-bromo-2-[(2-chloro-4-iodophenyl)amino]-N-(cyclopropylmethoxy)-3,4-difluorobenzamide
• Synonyms: 5-Bromo-2-[(2-chloro-4-iodophenyl)amino]-N-(cyclopropylmethoxy)-3,4-difluoro-benzamide; PF-1529483; PF-3011370; UK-287074; PD-184161; 5-Bromo-2-[(2-chloro-4-iodophenyl)amino]-N-(cyclopropylmethoxy)-3,4-difluorobenzamide; PD-184161

Database IDs

• CAS Number: 212631-67-9
• MDL Number: MFCD16038897
• PubChem SID: 162248952
• PubChem CID: 9937619

CALCULATED PROPERTIES

• Rotatable Bonds: 6
• Lipinski's Rule of Five: false
• Acid pKa: 11.691593
• H Acceptors: 3
• H Donor: 2
• LogD (pH = 5.5): 7.3063135
• LogD (pH = 7.4): 7.306294
• Log P: 7.306314
• Molar Refractivity: 108.0344 cm^3
• Polarizability: 41.00703 Å^3
• Polar Surface Area: 50.36 Å^2

PROPERTIES

Physical Property

• Solubility: DMSO: >10 mg/mL
• Apperance: white to off-white powder

Safety Information

• German water hazard class: 3
• GHS Pictograms: GHS09
• GHS Signal Word: Warning
• GHS Hazard statements: H400
• GHS Precautionary statements: P273
• Storage Temperature: 2-8°C

Product Information

• Purity: ≥98% (HPLC)
• Empirical Formula (Hill Notation): C17H13BrClF2IN2O2

DETAILS

Sigma Aldrich - PZ0112

Biochem/physiol Actions
PD-184161 is a MEK inhibitor.
Legal Information
Sold for research purposes under agreement from Pfizer Inc.

Toronto Research Chemicals - P218100

A novel mitogen-activated protein kinase kinase (MEK) inhibitor shown to exhibit antitumor effects and suppress MEK-extracellular signal-related kinase signaling activity and cell proliferation in human hepatocellular carcinoma cells and in human hepatoce

REFERENCES

• Yip-Schneider, M.T. et al.: J. Pharmacol. Exp. Therap., 329, 1063 (2009)
• Klein, P.J. et al.: Neoplasia, 8, 1 (2009)
• Yung, H.W. et al.: Biochem. Pharmacol., 68, 351 (2009)